{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "Results about the promising gout treatment Arcalyst come from a midstage trial involving a limited number of patients, but a larger study is planned for next year.", "headline": {"main": "A Regeneron Drug Minimized Recurrence of Gout in Clinical Trial", "print_headline": "Arcalyst, a Regeneron Drug, Minimized Recurrence of Gout in Clinical Trial"}, "abstract": null, "print_page": "3", "word_count": "531", "_id": "5477785979881006dca8ac02", "snippet": "Results about the promising gout treatment Arcalyst come from a midstage trial involving a limited number of patients, but a larger study is planned for next year.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2008/09/03/health/research/03gout.html", "multimedia": [], "subsection_name": "Research", "keywords": [{"value": "Regeneron Pharmaceuticals Incorporated", "is_major": "N", "rank": "1", "name": "organizations"}, {"value": "Gout", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Medicine and Health", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "5", "name": "subject"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2008-09-03T00:00:00Z", "section_name": "Health"}], "meta": {"hits": 1, "offset": 0, "time": 23}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}